Suppr超能文献

一种用于临床环境中同时测定血清中加巴喷丁、拉莫三嗪、左乙拉西坦、奥卡西平单羟基衍生物和唑尼沙胺浓度的超高效液相色谱-串联质谱法的开发与验证

Development and Validation of an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for the Concurrent Measurement of Gabapentin, Lamotrigine, Levetiracetam, Monohydroxy Derivative of Oxcarbazepine, and Zonisamide Concentrations in Serum in a Clinical Setting.

作者信息

Palte Michael J, Basu Sankha S, Dahlin Jameson L, Gencheva Ralitsa, Mason Donald, Jarolim Petr, Petrides Athena K

机构信息

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School.

Department of Pathology, Brigham and Women's Hospital, Boston, MA.

出版信息

Ther Drug Monit. 2018 Aug;40(4):469-476. doi: 10.1097/FTD.0000000000000516.

Abstract

BACKGROUND

Therapeutic drug monitoring of antiepileptic drugs (AEDs) is often necessary to prevent associated destructive toxicities. Tandem mass spectrometry (MS/MS) with stable-isotope-labeled internal standards is considered the gold standard for the measurement of AEDs. This study presents the development and validation of a clinical ultra-performance liquid chromatography-MS/MS method for the concurrent measurement of gabapentin, lamotrigine, levetiracetam, monohydroxy derivative of oxcarbazepine, and zonisamide in human serum.

METHODS

To determine the optimal assay analyte range, one year of AED therapeutic drug monitoring results (n = 1825) were evaluated. Simple protein precipitation with acetonitrile containing isotopically labeled internal standards was used. Reverse-phase ultra-performance liquid chromatography chromatographic separation was used, having a total run time of 3 minutes. Quantification of analytes was accomplished using electrospray ionization in positive ion mode and collision-induced dissociation MS. Assay parameters were evaluated per Food and Drug Administration bioanalytical guidelines.

RESULTS

After evaluating internal patient data, the analytical measuring range (AMR) of the assay was established as 0.1-100 mcg/mL. All AEDs were linear across the AMR, with R values ranging from 0.9988 to 0.9999. Imprecision (% coefficient of variation) and inaccuracy (% difference) were calculated to be <20% for the lower limit of quantitation and <15% for the low, mid, and high levels of quality controls across the AMR. All AEDs demonstrated acceptable assay parameters for carryover, stability under relevant storage conditions, matrix effects, recovery, and extraction and processing efficiency. In addition, the assay displayed acceptable concordance to results obtained from a national reference laboratory, with Deming regression R of 0.99 and slope values ranging from 0.89 to 1.17.

CONCLUSIONS

A simple, cost-effective, and robust ultra-performance liquid chromatography-tandem mass spectrometry method for monitoring multiple AEDs was developed and validated to address the clinical needs of patients at our institution.

摘要

背景

抗癫痫药物(AEDs)的治疗药物监测对于预防相关的破坏性毒性反应通常是必要的。采用稳定同位素标记内标的串联质谱法(MS/MS)被认为是测定AEDs的金标准。本研究介绍了一种用于同时测定人血清中加巴喷丁、拉莫三嗪、左乙拉西坦、奥卡西平单羟基衍生物和唑尼沙胺的临床超高效液相色谱 - MS/MS方法的开发与验证。

方法

为确定最佳分析物测定范围,评估了一年的AED治疗药物监测结果(n = 1825)。采用含同位素标记内标的乙腈进行简单蛋白沉淀。使用反相超高效液相色谱进行色谱分离,总运行时间为3分钟。采用正离子模式下的电喷雾电离和碰撞诱导解离质谱对分析物进行定量。按照美国食品药品监督管理局的生物分析指南评估分析方法参数。

结果

在评估患者内部数据后,该分析方法的分析测量范围(AMR)确定为0.1 - 100 mcg/mL。所有AEDs在AMR范围内呈线性,R值范围为0.9988至0.9999。定量下限的不精密度(变异系数百分比)和不准确程度(差异百分比)计算得出<20%,AMR范围内低、中、高质量控制水平的不精密度<15%。所有AEDs在残留、相关储存条件下的稳定性、基质效应、回收率以及提取和处理效率方面均显示出可接受的分析方法参数。此外,该分析方法与国家参考实验室获得的结果具有可接受的一致性,戴明回归R为0.99,斜率值范围为0.89至1.17。

结论

开发并验证了一种简单、经济高效且稳健的超高效液相色谱 - 串联质谱法,用于监测多种AEDs,以满足我们机构患者的临床需求。

相似文献

引用本文的文献

本文引用的文献

4
Advances in the development of biomarkers for epilepsy.癫痫生物标志物的研究进展。
Lancet Neurol. 2016 Jul;15(8):843-856. doi: 10.1016/S1474-4422(16)00112-5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验